In the other study that examined the efficacy and safety of combined therapy with trastuzumab, 5-FU, oxaliplatin, and docetaxel in HER2-positive patients, the proportion of patients with esophagogastric junction adenocarcinoma was 20%, and the overall treatment outcomes in all patients were as follows: response rate, 60%; median progression-free survival, 9.2 months; and median overall survival, 19.4 months [124]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.